« Back to Directory of Resources
Treatments Under Development
Here you will find a list of current treatments under development:
| Brand Name: | |
| Generic Name: | |
| Code Name: | SNS01-T |
| Company: | Senesco |
| FDA Clinical Phase: | 1/2 |
Description:
SNS01-T is a small inhibitory RNA molecule that blocks the expression of Factor 5A mRNA. The Factor 5A gene has been shown to regulate the expression of …
| Brand Name: | Bexxar |
| Generic Name: | iodine I 131 tositumomab |
| Code Name: | |
| Company: | GlaxoSmithKline |
| FDA Clinical Phase: | 2 |
Description:
Bexxar is a monoclonal antibody to which radioactive iodine 131 is attached, which targets a protein called CD20| Brand Name: | Doxil | |
| Generic Name: | doxorubicin HCl liposome injection | |
| Code Name: | ||
| Company: | Ortho Biotech | |
| FDA Clinical Phase: | 1,2, & 3 |
Description:
Doxil is a form of the anticancer drug doxorubicin that is contained in very tiny, fat-like particles.| Brand Name: | Aplidin |
| Generic Name: | plitidepsin |
| Code Name: | |
| Company: | PharmaMar, SA |
| FDA Clinical Phase: | 3 |
Description:
Aplidin is derived from a compound found in tunicates which shows promise in shrinking tumors.| Brand Name: | Torisel |
| Generic Name: | temsirolimus |
| Code Name: | |
| Company: | Pfizer |
| FDA Clinical Phase: | 1/2 |
Description:
Torisel, which is currently approved for treatment of advanced renal cell …
| Brand Name: | |
| Generic Name: | defibrotide |
| Code Name: | |
| Company: | Gentium SpA |
| FDA Clinical Phase: | 1/2 |
Description:
Defibrotide is an anticoagulant (a drug that prevents blood clotting) that may make myeloma cells more susceptible to chemotherapy. It is not an anti-tumor drug and …
